Cover Image
市場調查報告書

美國的診斷市場未來展望

US Diagnostic Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 226476
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
美國的診斷市場未來展望 US Diagnostic Market Outlook 2020
出版日期: 2015年09月01日 內容資訊: 英文 90 Pages
簡介

針對臨床檢驗的醫療費償付方針的修改,及對病期的早期發現的認識高漲、反映人口的高齡化,美國的診斷產品與服務市場顯示這幾年順利的成長。尤其預計,體外診斷(IVD)產品市場,預計2014∼2020年,以約6.3%的年複合成長率(CAGR)成長。

本報告提供美國的診斷設備、服務市場相關分析、市場主要推動因素、各產品/各疾病的產業概況與未來發展預測、主要企業簡介等、的調查評估,並將其結果為您概述為以下內容。

第1章 分析師的見解

第2章 分析方法

第3章 市場新趨勢與推動因素

  • 診斷方法:各種用途趨勢
  • 癌症診斷:產業相關人員的主要關注領域
  • 病患監測:來自診斷學進步的恩惠
  • 平均壽命的改善:促進診斷市場
  • 分子診斷學:病診斷的未來
  • 個體化醫療:革命的診斷法

第4章 產業概況

  • 醫療用影像設備
    • 核磁共振影像
    • 超音波檢驗
    • 電腦斷層攝影(CT)掃描機
    • X光掃描系統
  • 體外診斷(IVD)產品
    • 免疫分析法(免疫測量)
    • 臨床化學
    • 血液檢驗
    • 分子診斷
  • 各適應症的分類
    • 糖尿病
    • 心血管
    • 癌症
    • HIV

第5章 臨床檢驗服務市場

第6章 市場整合

第7章 競爭環境

  • 診斷用產品企業
    • Roche Holding Ltd
    • Johnson & Johnson
    • BioMerieux S.A.
    • Siemens AG
    • Becton, Dickinson and Company
    • Abbott Laboratories
    • Beckman Coulter, Inc
    • Hologic Inc.
    • QIAGEN
    • Thermo Fisher Scientific Inc.
  • 診斷服務企業
    • Quest Diagnostics Inc.
    • Laboratory Corporation of America Holdings
    • Genomic Health Inc.

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Diagnostic products and services in the US have been witnessing a steady demand over the past few years, backed by an increase in the insured population under Public Protection and Affordable Care Act, increasing awareness about early disease detection, increasing chronic diseases and an ever increasing aging population.

The US diagnostic market accounts for a major portion of the country's total healthcare market. The market growth is expected to grow in the coming years mainly due to segments, such as oncology, molecular diagnostics, point-of-care testing, personalized medicine and the associated companion diagnostics.

According to our research report, "US Diagnostic Market Outlook 2020", the US represents the world's largest and most matured diagnostic markets. Despite economic challenges and changes in the market environment in the wake of Patient Protection and Affordable Care Act, the US Diagnostics market has experienced a steady growth over the past few years. Looking ahead, the US market for diagnostic products is expected to slow down as the emerging markets offer a more lucrative business opportunity to the industry players. However, the US is expected to maintain its leading position as the world's largest IVD products market, growing at a moderate CAGR of 6.3% during 2014-2020.

Our segment-level analysis showed that the immunoassay market accounted for the largest market share of the total IVD products market. Although the segment is expected to witness a slow growth in the future due to competition from alternative technologies, especially molecular diagnostics, it is likely to sustain its topmost position in the market by 2020. Considering the growth rates, the market for molecular diagnostic IVD products is anticipated to outpace all the other segments, owing to selectivity, sensitivity, speed, accuracy, cost-effectiveness and breadth of application advantages over alternative IVDs.

Our report has been authored to evaluate the US diagnostic market potentials, and identify future growth opportunities. It provides extensive research and analysis on current market trends and future forecasts on all prominent diagnostic techniques including medical imaging and in vitro diagnostics.

The report also provides an insight into the market consolidation over the past few years, the competitive landscape of both the diagnostics and lab services market. The future analysis of the market scenario is likely to assist the intending clients to take informed and proactive business decisions in the evolving US diagnostic market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Emerging Market Trends and Drivers

  • 3.1 Diagnostics: Heading Towards Diversified Applications
  • 3.2 Cancer Diagnostics: Key Focus Area for Industry Players
  • 3.3 Patient Monitoring: Benefiting from Diagnostic Advancements
  • 3.4 Improving Life Expectancy: Stimulating Diagnostic Market
  • 3.5 Molecular Diagnostics: Future of Disease Diagnosis
  • 3.6 Personalized Medicine: Revolutionizing Diagnostics

4. Industry Overview

  • 4.1 Medical Imaging Equipments
    • 4.1.1 Magnetic Resonance Imaging
    • 4.1.2 Ultrasound
    • 4.1.3 Computed Tomography (CT) Scanners
    • 4.1.4 X-Ray Systems
  • 4.2 IVD Products
    • 4.2.1 Immunoassay
    • 4.2.2 Clinical Chemistry
    • 4.2.3 Blood Testing
    • 4.2.4 Molecular Diagnostics
  • 4.3 Segmentation by Indication
    • 4.3.1 Diabetes
    • 4.3.2 Cardiovascular
    • 4.3.3 Cancer
    • 4.3.4 HIV

5. Clinical Lab Services Market

6. Market Consolidations

7. Competitive Landscape

  • 7.1 By Diagnostic Products
    • 7.1.1 Roche Holding Ltd.
    • 7.1.2 Johnson & Johnson
    • 7.1.3 BioMérieux S.A.
    • 7.1.4 Siemens AG
    • 7.1.5 Becton Dickinson
    • 7.1.6 Abbott Laboratories
    • 7.1.7 Beckman Coulter Inc.
    • 7.1.8 Hologic Inc.
    • 7.1.9 QIAGEN
    • 7.1.10 Thermo Fisher Scientific Inc.
  • 7.2 By Services
    • 7.2.1 Quest Diagnostics Inc.
    • 7.2.2 Laboratory Corporation of America Holdings
    • 7.2.3 Genomic Health Inc.

List of Figures:

  • Figure 3-1: Patient Monitoring System Demand (Billion US$), 2014-2020
  • Figure 4-1: Medical Imaging Market Segmentation by Products (%), 2014
  • Figure 4-2: Medical Imaging Market Segmentation by Products (%), 2020
  • Figure 4-3: Medical Imaging Market (Billion US$), 2014-2020
  • Figure 4-4: Magnetic Resonance Imaging Market (Billion US$), 2014-2020
  • Figure 4-5: Ultrasound Imaging Market (Billion US$), 2014-2020
  • Figure 4-6: Computed Tomography (CT) Scanners Market (Billion US$), 2014-2020
  • Figure 4-7: X-Ray Systems Market (Billion US$), 2014-2020
  • Figure 4-8: IVD Products Market (Billion US$), 2014-2020
  • Figure 4-9: IVD Products Market by Clinical Segment (%), 2014
  • Figure 4-10: IVD Products Market by Clinical Segment (%), 2020
  • Figure 4-11: Immunoassay Diagnostics Market (Billion US$), 2014-2020
  • Figure 4-12: Clinical Chemistry Market (Billion US$), 2014-2020
  • Figure 4-13: Blood Testing Market (Billion US$), 2014-2020
  • Figure 4-14: Molecular Diagnostics Market (Billion US$), 2014-2020
  • Figure 4-15: Number of Diabetics in the US (Million), 2014 & 2030
  • Figure 4-16: Blood Glucose Monitoring Systems Market (Billion US$), 2014-2020
  • Figure 4-17: Cardiovascular Diagnostics Market (Billion US$), 2014-2020
  • Figure 4-18: Cancer Diagnostics Market (Billion US$), 2014-2020
  • Figure 5-1: Breakup of Clinical Lab Market by Services (%), 2014
  • Figure 5-2: Breakup of Outside Hospital Lab Services (%), 2014
  • Figure 5-3: Clinical Lab Services Market (Billion US$), 2014-2020

List of Tables:

  • Table 3-1: Life Expectancy and Prevalence of Diseases by Countries
  • Table 4-1: List of HIV Diagnostic Products
  • Table 6-1: Recent M&A in the US Diagnostics Market (2012 - 2015)
  • Table 7-1: Roche Holding Ltd. - Revenue by Business Segments (Million CHF), 2013 & 2014
  • Table 7-2: Roche Holding Ltd. - Strengths & Weaknesses
  • Table 7-3: Johnson & Johnson - Breakup of Medical Device Business (Million US$), 2013 & 2014
  • Table 7-4: Johnson & Johnson - Strengths & Weaknesses
  • Table 7-5: BioMerieux S.A. - Revenue by Business Segments (Million Euros), 2013 & 2014
  • Table 7-6: BioMérieux S.A. - Strengths & Weaknesses
  • Table 7-7: Siemens AG - Strengths & Weaknesses
  • Table 7-8: Becton Dickinson - Revenue by Business Segments (Million US$), 2013 & 2014
  • Table 7-9: Becton Dickinson - Strengths & Weaknesses
  • Table 7-10: Abbott Laboratories - Revenue by Business Segments (Million US$), 2013 & 2014
  • Table 7-11: Abbott Laboratories - Strengths & Weaknesses
  • Table 7-12: Beckman Coulter Inc. - Strengths & Weaknesses
  • Table 7-13: Hologic Inc. - Revenue by Business Segments (Million US$), 2013 & 2014
  • Table 7-14: Hologic Inc. - Strengths & Weaknesses
  • Table 7-15: QIAGEN - Strengths & Weaknesses
  • Table 7-16: Thermo Fisher Scientific Inc. - Revenue by Business Segments (Million US$), 2013 & 2014
  • Table 7-17: Thermo Fisher Scientific Inc. - Strengths & Weaknesses
  • Table 7-18: Quest Diagnostics Inc. - Strengths & Weaknesses
  • Table 7-19: Laboratory Corporation of America Holdings - Strengths & Weaknesses
  • Table 7-20: Genomic Health Inc. - Strengths & Weaknesses
Back to Top